Daewon Pharmaceutical Co. Ltd. (003220) - Total Liabilities
Based on the latest financial reports, Daewon Pharmaceutical Co. Ltd. (003220) has total liabilities worth ₩297.60 Billion KRW (≈ $201.68 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 003220 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Daewon Pharmaceutical Co. Ltd. - Total Liabilities Trend (2011–2025)
This chart illustrates how Daewon Pharmaceutical Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Check 003220 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Daewon Pharmaceutical Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Daewon Pharmaceutical Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OPPSTAR
KLSE:0275
|
Malaysia | RM7.21 Million |
|
Sona Topas Tourism Industry
JK:SONA
|
Indonesia | Rp280.21 Billion |
|
Lastminute.com NV
F:09B
|
Germany | €419.39 Million |
|
Beammwave AB B
ST:BEAMMW-B
|
Sweden | Skr8.02 Million |
|
SKY Metals Ltd
AU:SKY
|
Australia | AU$1.11 Million |
|
Smith-Midland Corp
NASDAQ:SMID
|
USA | $29.65 Million |
|
Apollo Silver Corp
V:APGO
|
Canada | CA$878.55K |
|
D&D Platform Reit Co Ltd
KO:377190
|
Korea | ₩683.38 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Daewon Pharmaceutical Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Daewon Pharmaceutical Co. Ltd..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daewon Pharmaceutical Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daewon Pharmaceutical Co. Ltd. (2011–2025)
The table below shows the annual total liabilities of Daewon Pharmaceutical Co. Ltd. from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩339.07 Billion ≈ $229.78 Million |
+13.47% |
| 2024-12-31 | ₩298.81 Billion ≈ $202.50 Million |
+22.60% |
| 2023-12-31 | ₩243.73 Billion ≈ $165.17 Million |
+19.02% |
| 2022-12-31 | ₩204.78 Billion ≈ $138.78 Million |
-3.03% |
| 2021-12-31 | ₩211.18 Billion ≈ $143.11 Million |
+72.47% |
| 2020-12-31 | ₩122.44 Billion ≈ $82.98 Million |
-0.71% |
| 2019-12-31 | ₩123.32 Billion ≈ $83.57 Million |
+33.69% |
| 2018-12-31 | ₩92.24 Billion ≈ $62.51 Million |
+56.15% |
| 2017-12-31 | ₩59.07 Billion ≈ $40.03 Million |
+12.16% |
| 2016-12-31 | ₩52.67 Billion ≈ $35.69 Million |
+14.28% |
| 2015-12-31 | ₩46.09 Billion ≈ $31.23 Million |
-0.04% |
| 2014-12-31 | ₩46.11 Billion ≈ $31.25 Million |
+24.99% |
| 2013-12-31 | ₩36.89 Billion ≈ $25.00 Million |
+7.86% |
| 2012-12-31 | ₩34.20 Billion ≈ $23.18 Million |
-6.23% |
| 2011-12-31 | ₩36.47 Billion ≈ $24.72 Million |
-- |
About Daewon Pharmaceutical Co. Ltd.
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemuls… Read more